EP0563145A1 - Chelating agents - Google Patents

Chelating agents

Info

Publication number
EP0563145A1
EP0563145A1 EP92901385A EP92901385A EP0563145A1 EP 0563145 A1 EP0563145 A1 EP 0563145A1 EP 92901385 A EP92901385 A EP 92901385A EP 92901385 A EP92901385 A EP 92901385A EP 0563145 A1 EP0563145 A1 EP 0563145A1
Authority
EP
European Patent Office
Prior art keywords
group
compound
groups
formula
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901385A
Other languages
German (de)
French (fr)
Inventor
Per Strande
Jo Klaveness
P L Rongved
Harald Dugstad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed AS filed Critical Nycomed AS
Publication of EP0563145A1 publication Critical patent/EP0563145A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the present invention relates to chelating agents, more particularly aminopolycarboxylic acid chelants, and metal chelates thereof and the use of such chelating agents and chelates in diagnostic imaging, radiotherapy or heavy metal detoxification, and in particular as hepatobiliary contrast agents.
  • APCAs are well known as particularly effective chelants and are described in a wide range of publications, for example in US-A-2407645 (Bersworth), EP-A-71564 (Schering), EP-A-130934
  • EP-A-71564 describes
  • paramagnetic metal chelates for which the chelating agent is nitrilotriacetic acid (NTA),
  • DTPA N-hydroxyethylimino-diacetic acid
  • contrast agents for MRI contrast being achieved by the effect of the magnetic field of the paramagnetic species (e.g. Gd(III)) with the chelating agents serving to reduce the toxicity and to assist administration of the paramagnetic species.
  • EP-A-71564 was the dimeglumine salt of GdDTPA, the use of which as an MRI contrast agent has recently received much attention.
  • Salutar Inc in for example US-A-4687659, has proposed the use as MRI contrast agents of chelates of paramagnetic metal ions and bisamides of DTPA, in particular DTPA-bismethylamide.
  • Salutar suggested that for imaging of the liver chelates of DTPA-bis (higher alkyl-amides) might be used.
  • EHPG ethylene-bis-(2-hydroxyphenyl glycine)
  • HBED bis (2-hydroxybenzyl)-ethylenediamine diacetic acid
  • benzo- and dibenzo-DTPA triaza and tetraaza
  • GdBOPTA in which the chelant BOPTA has a DTPA structure with one N 3 carboxymethyl replaced by a 2-benzyloxy-1-carboxy-ethyl group.
  • GdBOPTA has been described by Vittadini et al in CMR '89, MR19 as a liver-specific MRI contrast agent.
  • hydrophilic groupings such as hydroxyl and alkoxy groups.
  • n 0 or 1
  • R 1 is a group NR 11 R 14 where R 11 is a hydroxyl or alkoxy group or a group -L-Cy or -O-L-Cy, and R 14 is a hydrogen atom, an alkyl group or a group -L-Cy, and the other group R 1 is a hydroxyl group or a group NR 11 R 14 ;
  • L is a bond or a straight-chain or branched saturated or unsaturated alkylene group optionally interrupted by a carbocyclic or heterocyclic saturated or unsaturated group and optionally attached to the Cy group by a peptide or carbonyl link and optionally substituted by further Cy groups or by aminocarbonyl, acyl or acylamino groups; and Cy is a cyclic lipophilic group, eg a carbocyclic or heterocyclic saturated or unsaturated group itself optionally carrying one or more fused carbocyclic or heterocyclic saturated or unsaturated rings and optionally substituted by halogen atoms
  • alkyl or alkylene moieties in the compounds of the invention preferably contain up to 10, particularly preferably up to 6, carbon atoms.
  • the lipophilic Cy groups and the other cyclic rings in the compounds of formula I are
  • rings particularly preferably mono or polycyclic groups containing 5 to 7 ring members in each ring, the rings if heterocyclic containing up to 3, preferably 1 or 2 , non-adjacent ring heteroatoms selected from O, N and S.
  • Preferred such rings include benzene, pyridine,
  • pyrimidine pyrazine, 1,3-oxazine, 1,4-oxazine, 1,3-thiazine, 1,4-thiazine, pyrrole, imidazole, 1,3-oxazole, 1,3-thiazole, furan, thiophene, piperidine, piperazine, morpholine, perhydro-1,4-thiazine and pyrrolidine.
  • lipophilic Cy groups include groups of formula la to Ie
  • R 3 to R 8 is each independently a bond or a
  • linker moiety L is conveniently a branched or linear alkylene chain, eg such that LCy is of formula
  • each R 10 is a hydrogen atom, an alkyl group, an optionally esterified carboxyl group or a group Cy, at least one and preferably only one being a group Cy, and one or more CHR 10 moieties may optionally be replaced by a 5-7 membered saturated homo or heterocyclic ring.
  • the carboxyl groups in the compounds of formula I may, for example, be in the form of carboxylate salt groups, for example groups of formula -COOMt (where Mt is a monovalent cation or a fraction of a polyvalent cation, for example an ammonium or substituted ammonium ion or a metal ion, for example an alkali metal or alkaline earth metal ion).
  • Mt + is a cation deriving from an organic base, for example meglumine.
  • the number of the ion-forming carboxyl groups in the compounds of formula I be chosen to equal the valency of the metal species to be chelated by the compound of formula I.
  • the chelating agent of formula I preferably contains three ion-forming -COOH or -COOMt groups.
  • the metal chelate will be formed as a neutral species, a form preferred since the osmotic pressures in
  • the compounds of the invention contain two -L-Cy groups and particularly preferred compounds according to the invention include the chelants of formula II
  • R 15 is hydrogen or methyl and R 13 is a group selected from benzyl, 2-phenyl-ethyl, 1-phenyl-ethyl, pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 3- morpholino-propyl, N-benzyl-piperidin-4-yl and indanyl groups and iodinated such groups), and the metal
  • the chelant compounds of the invention may be prepared by amidation, eg analogously to EP-A-130934 (Schering) and US-A-4687659 (Salutar) of EDTA or DTPA or an activated or protected derivative thereof (eg an acid anhydride or bisanhydride) with an amine compound of formula III
  • R 11 ' and R 14 ' are groups R 11 and R 14 as hereinbefore defined or protected such groups), followed where necessary by deprotection.
  • protecting groups conventional protecting groups may be used, for example groups such as are described by T.W. Greene in "Protective Groups in
  • the compounds may be prepared in two or more stages, in the first reacting DTPA, EDTA or a derivative thereof to introduce one or two NR 11 " R 14 " groups (where one of R 11 " and R 14 " is a group R 11 ' or R 14 ' and the other is a Cy-free analogues of R 11 ' or R 14 ') and in a second stage to introduce the Cy groups, eg by a peptide condensation reaction.
  • the amidation reactions are preferably performed in the liquid phase.
  • a solution of the amine in a solvent such as water, dipolar aprotic solvents, such as acetonitrile, N-methylpyrrolidone, N-methylmorpholine, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran and the like or mixtures thereof is prepared.
  • the anhydride is added in portions or optionally dissolved in a dipolar aprotic anhydrous solvent such as acetonitrile, N- methylpyrrolidone, N-methylmorpholine,
  • reaction mixture is stirred under a nitrogen atmosphere for a period ranging between 0.5 hour and 3 days, preferably between 1 hour and 24 hours.
  • the reaction temperatures generally range between about 0°C and 100°C, temperatures of about 20°C to 80°C being preferred.
  • solvents with a low boiling point 100oC or less
  • the reaction mixture can eventually be
  • the bisamide chelants may be prepared by amidation as follows: a) the amine of formula III is dissolved in a dry polar aprotic solvent, e.g. acetonitrile or chloroform, in a ratio of about 1:10 w:v amine: solvent.
  • a dry polar aprotic solvent e.g. acetonitrile or chloroform
  • the product may be purified as follows: the precipitate from a) is dissolved in deionized water, and if necessary the pH is adjusted to 8-10 using dilute NaOH. The pH is then adjusted to 3-3.5 with dilute HC1, and the precipitate is collected by filtration.
  • Chelants of formula I may be used as the basis for bifunctional chelants or for polychelant compounds, that is compounds containing several independent chelant groups, by substituting for a hydrogen atom or hydroxyl group a bond or linkage to a macromolecule or polymer, e.g. a tissue specific biomolecule or a backbone polymer such as polylysine or polyethyleneimine which may carry several chelant groups and may itself be attached to a macromolecule to produce a bifunctional-polychelant.
  • a macromolecule or polymer e.g. a tissue specific biomolecule or a backbone polymer such as polylysine or polyethyleneimine which may carry several chelant groups and may itself be attached to a macromolecule to produce a bifunctional-polychelant.
  • Such macromelecular derivatives of the compounds of formula I and the salts and metal chelates thereof form a further aspect of the present invention.
  • macromolecule or backbone polymer may be effected by any of the conventional methods such as the carbodiimide method, the mixed anhydride procedure of Krejcarek et al. (see Biochemical and Biophysical Research
  • Formation of salts and chelates of the chelants of the invention may again be performed in a conventional manner.
  • the chelating agents of the present invention are particularly suitable for use in detoxification or in the formation of metal chelates, chelates which may be used for example in or as contrast agents for in vivo or in vitro magnetic resonance (MR), X-ray or ultrasound diagnostics (e.g. MR imaging and MR spectroscopy), or scintigraphy or in or as therapeutic agents for
  • Salts or chelate complexes of the compounds of the invention containing heavy metal ions are particularly useful in diagnostic imaging or therapy. Especially preferred are salts or complexes with metals of atomic numbers 20-32, 42-44, 49 and 57 to 83, particularly Gd, Dy and Yb.
  • the chelated metal ion is particularly suitably a
  • paramagnetic ion the metal conveniently being a
  • transition metal or a lanthanide preferably having an atomic number of 21-29, 42, 44 or 57-71.
  • Metal chelates in which the metal species is Eu, Gd, Dy, Ho, Cr, Mn or Fe are especially preferred and Gd , Mn and Dy are particularly preferred.
  • the paramagnetic metal species is conveniently non-radioactive as
  • the chelated metal species is preferably a heavy metal species, for example a non-radioactive metal with an atomic number greater than 37, preferably greater than 50, e.g. Dy 3+ .
  • the chelated metal species must of course be radioactive and any conventional complexable radioactive metal isotope, such as 99m Tc or 111 In for example, may be used.
  • the chelating agent may be in the form of a metal chelate with for example 67 Cu, 153 Sm or 90 Y.
  • the chelating agent For use in detoxification of heavy metals, the chelating agent must be in salt form with a
  • physiologically acceptable counterion e.g. sodium, calcium, ammonium, zinc or meglumine, e.g. as the sodium salt of the chelate of the compound of formula I with zinc or calcium.
  • metal chelate carries an overall charge, such as is the case with the prior art Gd DTPA, it will conveniently be used in the form of a salt with a
  • physiologically acceptable counterion for example an ammonium, substituted ammonium, alkali metal or alkaline earth metal cation or an anion deriving from an
  • meglumine salts are particularly preferred.
  • the present invention provides a diagnostic or therapeutic agent comprising a metal chelate, whereof the chelating entity is the residue of a compound of formula I or salt thereof, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation
  • the present invention provides a detoxification agent comprising a chelating agent according to the invention in the form of salt with a physiologically acceptable counterion, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation therewith or for inclusion in a pharmaceutical formulation for human or veterinary use.
  • the diagnostic and therapeutic agents of the present invention may be formulated with conventional pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. and may be in a form suitable for parenteral or enteral
  • agent of the present invention may be in a conventional
  • compositions such as a tablet, capsule, powder, solution, suspension, dispersion, syrup, suppository, etc; however, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.
  • the compounds according to the invention may therefore be formulated for administration using
  • Suitable additives include, for example, physiologically
  • biocompatible buffers as for example, tromethamine hydrochloride
  • additions e.g., 0.01 to 10 mole
  • chelants such as, for example, DTPA, a DTPA-bisamide or non-complexed chelants of formula I
  • calcium chelate complexes as for example calcium DTPA, CaNaDTPA-bisamide, calcium salts or chelates of chelants of formula I
  • additions e.g., 1 to 50 mole percent
  • calcium of sodium salts for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate combined with metal chelate complexes of chelants formula I and the like.
  • a small amount of soluble chelate may be mixed with one or more of the inactive ingredients traditionally present in oral solutions and/or
  • the most preferred mode for administering metal chelates as contrast agents is parenteral, e.g.,
  • parenterally administrable forms e.g., intravenous solutions
  • Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium
  • solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will not interfere with the manufacture, storage or use of products.
  • the diagnostic or therapeutic agent comprises a chelate or salt of a toxic metal species, e.g. a heavy metal ion
  • a chelate or salt of a toxic metal species e.g. a heavy metal ion
  • the diagnostic agent of the present invention if in solution, suspension or dispersion form, will generally contain the metal chelate at concentration in the range 1 micromole to 1.5 mole per litre, preferably 0.1 to 700mM.
  • the diagnostic agent may however be supplied in a more concentrated form for dilution prior to administration.
  • diagnostic agent of the invention may conveniently be admi .ni.stered in amounts of from 10-3 to 3 mmol of the metal species per kilogram of body weight, e.g. about 1 mmol Gd/kg bodyweight.
  • the dose of the contrast agent should generally be higher and for scintigraphic examination the dose should generally be lower than for MR examination.
  • conventional dosages may be used for radiotherapy and detoxification.
  • the present invention provides a method of generating enhanced images of the human or non-human animal body, especially the liver, which method comprises administering to said body a diagnostic agent according to the present invention and generating an X-ray, MR-diagnostics, ultrasound or scintigraphic image of at least a part thereof.
  • the present invention provides a method of radiotherapy practised on the human or non-human animal body, which method comprises
  • the present invention provides a method of heavy metal detoxification
  • a chelating agent according to the invention in the form of a salt with a physiologically acceptable counterion.
  • the present invention also provides the use of the compounds, especially the metal chelates, according to the
  • the present invention provides a process for the preparation of the metal chelates of the invention which process comprises admixing in a solvent a compound of formula I or a salt (e.g. the sodium salt) or chelate thereof together with an at least sparingly soluble compound of said metal, for example a chloride, oxide or carbonate.
  • a solvent e.g. the sodium salt
  • an at least sparingly soluble compound of said metal for example a chloride, oxide or carbonate.
  • the present invention provides a process for the preparation of the diagnostic or therapeutic agent of the present invention
  • the present invention provides a process for the preparation of the detoxification agent of the invention, which comprises admixing a chelating agent according to the invention in the form of a salt with a physiologically acceptable counterion together with at least one pharmaceutical or veterinary carrier or excipient.
  • EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 1-phenylethylamine 0.9 g (7.8 mmol) in dried acetonitrile (40 ml) at ambient
  • the crude solid was dissolved in 20 ml water to which was added 1N NaOH to bring the pH to 10.
  • DTPA-bis(anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 2-phenylethylamine 0.68 g (5.6 mmol) in dried chloroform (85 ml) at ambient
  • DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 2-aminomethylpyridine 0.61 g (5.6 mmol) in dried chloroform at ambient temperature. The stirred solution was left for 42 hours at ambient temperature. The precipitate formed was isolated by filtration and dried.
  • DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 4-amino-1-benzylpiperidine 1.07 g (5.6 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was then heated to reflux temperature. The solution was refluxed with stirring overnight under a nitrogen atmosphere. The solution was then evaporated until 25-30 ml remained. Subsequently ether (120ml) was added, and the precipitate was
  • DTPA-bis (anhydride) 0.88 g (2.48 mmol) was gradually added to a stirred solution of 2-aminoindane 0.66 g (4.955 mmol) in dried acetonitrile (40 ml) at ambient temperature. The solution was heated to reflux
  • EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of benzylamine 0.83 g (3.9 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was heated to reflux temperature (70°C) and refluxed under a nitrogen atmosphere for 19 hours. The reaction mixture was subsequently cooled, and the precipitate formed was filtered off and dried.
  • 1,4,7,10-Tetraaza-4,7-bis(carboxymethyl)-2,9-dioxo-1,10-bis(pyrid-2-yl) decane lg (3,9 mmol) EDTA-bis (anhydride) was gradually under stirring to acetonitrile (33 ml) heated to boiling. The mixture was refluxed for 1/2 h and 0.73g (1.1 mmol) 2-aminopyridine dissolved in 7 ml acetonitrile was
  • DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 4-amino-1-benzylpiperidine 1.07 g (5.6 mmol) in dried chloroform (100 ml) at ambient temperature. The stirred solution was left at ambient temperature for 66 hours. Then about 50% of the chloroform was evaporated off. Ether (50 ml) was then added, and the precipitate formed was filtered off and dried.
  • DTPA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 4-amino-l-benzylpiperidine 1.48 g (7.8 mmol) in dried chloroform (85 ml) at ambient temperature. The stirred solution was left for 18 hours at ambient temperature. The solution was evaporated until 25-30 ml remained. Subsequently ether (2 ⁇ 100 ml) was added. The precipitate formed was isolated by filtration and dried.
  • DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of N-(3-aminopropyl)morpholine 0.81 g (5.6 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was stirred for 27 hours and then refluxed under a nitrogen atmosphere for 69 hours. The solution was evaporated until 25-30 ml remained.
  • DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 3-aminomethylpyridine 0.61 g (5.6 mmol) in dried acetonitrile (40 ml) at ambient temperature. The solution was stirred for 84 hours. The precipitate formed was isolated by filtration and dried.
  • EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 2-aminomethylpyridine 0.84 g (7.8 mmol) in dried chloroform (120 ml) at ambient temperature. The stirred solution was left for 16 hours at ambient temperature. The solution was evaporated until 25-30 ml remained. Subsequently ether (50 ml) was added. The precipitate formed was isolated by
  • DTPA-bis (anhydride) (0.56 g, 1.56 mmol) was added in portions to a solution of H-Phe-OBzl-HCl (0.91 g, 3.12 mmol) and triethylamine (0.32 g, 3.12 mmol) in
  • Triethylamine (0.57 g, 5.6 mmol), tryptophanmethylester (HCl) (1.43 g, 5.6 mmol) and DTPA-bis (anhydride) (1.000 g, 2.8 mmol) were dissolved in 100 ml chloroform. The mixture was refluxed in a nitrogen atmosphere for 3 days. Most of the chloroform was removed (20-30 ml left). 100 ml diethylether was added to the
  • Lithium hydroxide (14.4 mg, 0.61 mmol) was dissolved in a 4.5 ml mixture of MeOH/H 2 O(3:1). 3,6,9,12-Tetraaza- 2,13,-bis(methyloxycarbonyl)-6,9-bis(carboxymethyl)- 4,11-dioxo-1,14-bis(indol-3-yl)tetradecane (60.0 mg, 8.7 ⁇ 10 -2 mmol) was added and the solution was stirred for 8 hours. Methanol was removed, 2 ml water was added and the pH was adjusted to 3.5 (0.5 M HCl). The solid product was collected and dried in vacuo for 12 hours. The identity of the product as the title compound was verified by 1 ⁇ . NMR.
  • Lithium hydroxide (0.32 g, 13.4 mmol) was dissolved in a mixture of MeOH/H 2 O (3:1). 3,6,9,12,15-Pentaaza-2,16,-bis(methyloxycarbonyl)-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-bis(indol-3-yl)heptadecane (1.33 g, 1.67 mmol) was added and the solution was stirred for 6 hours at ambient temperature. Methanol was evaporated and 10 ml water was added to the residual. The pH was adjusted to 3.5 with 0.5 M HCl. The solid product was collected by filtration and dried to give 18% product.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des chélateurs de formule (I) dans laquelle n vaut 0 ou 1 et au moins un groupe R1 comprend un groupe NR11R14 dans lequel R11 ou R14 comprend un groupe lipophilique cyclique. L'invention concerne également des chélates métalliques et des sels desdits chélateurs. Les chélates possédant des ions métal de lourd ou paramagnétiques sont particulièrement utiles comme agents de contraste hépatobiliaires.The invention relates to chelators of formula (I) in which n is 0 or 1 and at least one group R1 comprises a group NR11R14 in which R11 or R14 comprises a cyclic lipophilic group. The invention also relates to metal chelates and salts of said chelators. Chelates having heavy or paramagnetic metal ions are particularly useful as hepatobiliary contrast agents.

Description

CHELATING AGENTS
The present invention relates to chelating agents, more particularly aminopolycarboxylic acid chelants, and metal chelates thereof and the use of such chelating agents and chelates in diagnostic imaging, radiotherapy or heavy metal detoxification, and in particular as hepatobiliary contrast agents.
Medical uses of chelating agents are well
established, for example as stabilizers for
pharmaceutical preparations, as antidotes for poisonous heavy metal species and as agents for the
administration, in chelate form, of metal ions for radiotherapy or diagnostic imaging, e.g. X-ray, magnetic resonance imaging (MRI), ultrasound or scintigraphy. Aminopolycarboxylic acids and derivatives thereof
(hereinafter referred to as APCAs) are well known as particularly effective chelants and are described in a wide range of publications, for example in US-A-2407645 (Bersworth), EP-A-71564 (Schering), EP-A-130934
(Schering), EP-A-165728 (Nycomed), US-A-4647447
(Schering), US-A-4826673 (Mallinckrodt), US-A-4639365 (Sherry), EP-A-263059 (Schering), EP-A-230893 (Bracco), EP-A-325762 (Bracco), WO-A-86/06605 (Lauffer), US-A-4746507 (Salutar), EP-A-290047 (Salutar), WO-A-90/01024 (Mallinckrodt), US-A-4687659 (Salutar) and EP-A-299795 (Nycomed) and in the documents cited in these patent publications.
Thus, for example, EP-A-71564 describes
paramagnetic metal chelates, for which the chelating agent is nitrilotriacetic acid (NTA),
N,N,N',N'-ethylenedι.amι.netetraacetιc aci.d (EDTA),
N-hydroxyethyl-N,N",N'-ethylenediaminetriacetic acid
(HEDTA), N,N,N',N",N"-diethylenetriaminepentaacetic acid
(DTPA) and N-hydroxyethylimino-diacetic acid, as being suitable as contrast agents for MRI, contrast being achieved by the effect of the magnetic field of the paramagnetic species (e.g. Gd(III)) with the chelating agents serving to reduce the toxicity and to assist administration of the paramagnetic species.
Amongst the particular metal chelates disclosed by EP-A-71564 was the dimeglumine salt of GdDTPA, the use of which as an MRI contrast agent has recently received much attention.
To improve stability, water solubility and
selectivity, relative to the APCA chelating agents described in EP-A-71564, Schering in EP-A-130934 proposed the partial substitution for the N-attached carboxyalkyl groups of alkyl, alkoxyalkyl,
alkoxycarbonylalkyl or alkylaminocarbonylalkyl groups, where any amide nitrogens may themselves carry
polyhydroxy-alkyl groups.
For reduced toxicity, Salutar Inc, in for example US-A-4687659, has proposed the use as MRI contrast agents of chelates of paramagnetic metal ions and bisamides of DTPA, in particular DTPA-bismethylamide. In the same patent, Salutar suggested that for imaging of the liver chelates of DTPA-bis (higher alkyl-amides) might be used.
In this field of hepatobiliary MRI contrast agents Nycomed, in EP-A-165728, have also proposed the use of paramagnetic chelates of certain anilide group-containing iminodiacetic acids and Lauffer in WO-A-86/06605 has suggested the use of paramagnetic chelates of various benzene ring containing chelants, e.g.
ethylene-bis-(2-hydroxyphenyl glycine) (EHPG), bis (2-hydroxybenzyl)-ethylenediamine diacetic acid (HBED), benzo- and dibenzo-DTPA and triaza and tetraaza
macrocycles which carry a fused benzene ring.
Still further APCA chelants for use in preparing MRI contrast agents have been proposed by Bracco in EP-A-230893 and EP-A-325762. These for the most part carry aryl or aralkyl substituents on the alkylene part of one or more of the nitrogen-attached carboxyalkyl complexforming moieties. Among the chelates covered is
GdBOPTA, in which the chelant BOPTA has a DTPA structure with one N3 carboxymethyl replaced by a 2-benzyloxy-1-carboxy-ethyl group. GdBOPTA has been described by Vittadini et al in CMR '89, MR19 as a liver-specific MRI contrast agent.
Schering in EP-A-263059 have proposed a further range of DTPA and EDTA amide chelants for use in
preparing MRI contrast agents. While commenting on the high lipophilicity of the DTPA-bisamides proposed by Salutar in WO-A-86/02841 (equivalent to US-A-4687659 discussed above), Schering have exemplified such
compounds as GdDTPA-bispentylamide, GdDTPA-bisbutylamide and GdDTPA-phenylamide as well as chelates of further DTPA-alkylamides in which the alkyl moieties are
substituted by hydrophilic groupings such as hydroxyl and alkoxy groups.
There is however a general and continuing need for APCA chelants which form metal chelates of reduced toxicity, improved stability, improved water solubility or improved biodistribution (e.g. enhanced tissue or organ specificity).
We now propose certain improved chelating agents, in particular amide derivatives of APCAs.
Viewed from one aspect therefore the invention provides chelants of formula I
(wherein n is 0 or 1;
one group R1 is a group NR11R14 where R11 is a hydroxyl or alkoxy group or a group -L-Cy or -O-L-Cy, and R14 is a hydrogen atom, an alkyl group or a group -L-Cy, and the other group R1 is a hydroxyl group or a group NR11R14; L is a bond or a straight-chain or branched saturated or unsaturated alkylene group optionally interrupted by a carbocyclic or heterocyclic saturated or unsaturated group and optionally attached to the Cy group by a peptide or carbonyl link and optionally substituted by further Cy groups or by aminocarbonyl, acyl or acylamino groups; and Cy is a cyclic lipophilic group, eg a carbocyclic or heterocyclic saturated or unsaturated group itself optionally carrying one or more fused carbocyclic or heterocyclic saturated or unsaturated rings and optionally substituted by halogen atoms (eg iodine, chlorine or bromine), alkyl, alkylamino,
dialkylamino, carbamoyl, N-alkylcarbamoyl, acetamido, N- alkylacetamido and carbocyclic or heterocyclic saturated or unsaturated groups; with the provisos that in any NR11R14 group one of R11 and R14 group comprises a L-Cy group and that where n is 1 at least one R1 is other than phenylamine, benzylamine or methoxybenzylamine) and metal chelates and salts thereof.
Unless specified otherwise, all alkyl or alkylene moieties in the compounds of the invention preferably contain up to 10, particularly preferably up to 6, carbon atoms. The lipophilic Cy groups and the other cyclic rings in the compounds of formula I are
particularly preferably mono or polycyclic groups containing 5 to 7 ring members in each ring, the rings if heterocyclic containing up to 3, preferably 1 or 2 , non-adjacent ring heteroatoms selected from O, N and S. Preferred such rings include benzene, pyridine,
pyrimidine, pyrazine, 1,3-oxazine, 1,4-oxazine, 1,3-thiazine, 1,4-thiazine, pyrrole, imidazole, 1,3-oxazole, 1,3-thiazole, furan, thiophene, piperidine, piperazine, morpholine, perhydro-1,4-thiazine and pyrrolidine.
Thus particular examples of lipophilic Cy groups include groups of formula la to Ie
and other condensed acyclic rings
(where R3 to R8 is each independently a bond or a
hydrogen or halogen atom or an alkyl, alkylamino, dialkylamino, carbamoyl, N-alkylcarbamoyl, acetamido or N-alkylacetamido group or two adjacent groups from R3 to R8 together form a C2-5 alkylene or azaalkylene bridge, the point of attachment to L being a carbon of said bridge or one of said groups R3 to R8; X is nitrogen or CH and Y is CH or nitrogen; X1 is CH2, NH, oxygen, sulphur or a bond; X" is nitrogen, oxygen or sulphur and Y" is CH or nitrogen; and R9 is a bond or hydrogen, alkyl or aralkyl, eg benzyl; such rings preferably not having ring heteroatoms at adjacent ring positions).
The linker moiety L is conveniently a branched or linear alkylene chain, eg such that LCy is of formula
-(CHR10)k-(CO)a-(NR10)b-(CO)C-R10 where k is 0-10, especially 1 to 8, more especially 1 to 6; a, b and c are 0 or 1, the sum of a and c being 0 or
1; each R10 is a hydrogen atom, an alkyl group, an optionally esterified carboxyl group or a group Cy, at least one and preferably only one being a group Cy, and one or more CHR10 moieties may optionally be replaced by a 5-7 membered saturated homo or heterocyclic ring.
The carboxyl groups in the compounds of formula I may, for example, be in the form of carboxylate salt groups, for example groups of formula -COOMt (where Mt is a monovalent cation or a fraction of a polyvalent cation, for example an ammonium or substituted ammonium ion or a metal ion, for example an alkali metal or alkaline earth metal ion). Particularly preferably, Mt+ is a cation deriving from an organic base, for example meglumine.
It is also particularly preferred that the number of the ion-forming carboxyl groups in the compounds of formula I be chosen to equal the valency of the metal species to be chelated by the compound of formula I.
Thus, for example, where Gd(III) is to be chelated, the chelating agent of formula I preferably contains three ion-forming -COOH or -COOMt groups. In this way, the metal chelate will be formed as a neutral species, a form preferred since the osmotic pressures in
concentrated solutions of such compounds are low and since their toxicities relative to their ionic analogues are significantly reduced.
Preferably the compounds of the invention contain two -L-Cy groups and particularly preferred compounds according to the invention include the chelants of formula II
(where n is 0 or 1 , R15 is hydrogen or methyl and R13 is a group selected from benzyl, 2-phenyl-ethyl, 1-phenyl-ethyl, pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 3- morpholino-propyl, N-benzyl-piperidin-4-yl and indanyl groups and iodinated such groups), and the metal
chelates and salts thereof.
The chelant compounds of the invention may be prepared by amidation, eg analogously to EP-A-130934 (Schering) and US-A-4687659 (Salutar) of EDTA or DTPA or an activated or protected derivative thereof (eg an acid anhydride or bisanhydride) with an amine compound of formula III
HNR11'R14' (III)
(where R11' and R14' are groups R11 and R14 as hereinbefore defined or protected such groups), followed where necessary by deprotection.
As protecting groups, conventional protecting groups may be used, for example groups such as are described by T.W. Greene in "Protective Groups in
Organic Synthesis", John Wiley & Sons, 1981.
Alternatively the compounds may be prepared in two or more stages, in the first reacting DTPA, EDTA or a derivative thereof to introduce one or two NR11" R14" groups (where one of R11" and R14" is a group R11' or R14' and the other is a Cy-free analogues of R11' or R14') and in a second stage to introduce the Cy groups, eg by a peptide condensation reaction.
The amidation reactions are preferably performed in the liquid phase. Thus for example a solution of the amine in a solvent such as water, dipolar aprotic solvents, such as acetonitrile, N-methylpyrrolidone, N-methylmorpholine, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran and the like or mixtures thereof is prepared. The anhydride is added in portions or optionally dissolved in a dipolar aprotic anhydrous solvent such as acetonitrile, N- methylpyrrolidone, N-methylmorpholine,
dimethylformamide, dimethylacetamide, dimethyl
sulfoxide, tetrahydrofuran and the like or mixtures thereof. The reaction mixture is stirred under a nitrogen atmosphere for a period ranging between 0.5 hour and 3 days, preferably between 1 hour and 24 hours. The reaction temperatures generally range between about 0°C and 100°C, temperatures of about 20°C to 80°C being preferred. For solvents with a low boiling point (100ºC or less) the reaction mixture can eventually be
evaporated to dryness. For the solvents with higher boiling points, further solvents such as for example diethylether may be added and/or cooling may be used to precipitate the product.
Thus for example the bisamide chelants may be prepared by amidation as follows: a) the amine of formula III is dissolved in a dry polar aprotic solvent, e.g. acetonitrile or chloroform, in a ratio of about 1:10 w:v amine: solvent. The
bisanhydride of DTPA (or EDTA) (0.5 equivalents to the amine) is added as dry powder in portions, with thorough stirring, and the reaction is allowed to proceed
overnight. In the case of less reactive amines such as for example 2-aminopyridine, extensive refluxing may be necessary. In most cases the product precipitates from the reaction mixture and can be collected by filtration. Otherwise the product can be precipitated by addition of diethyl ether and/or by cooling.
In the case of the bis-amides with non-heterocyclic side groups, the product may be purified as follows: the precipitate from a) is dissolved in deionized water, and if necessary the pH is adjusted to 8-10 using dilute NaOH. The pH is then adjusted to 3-3.5 with dilute HC1, and the precipitate is collected by filtration.
Chelants of formula I may be used as the basis for bifunctional chelants or for polychelant compounds, that is compounds containing several independent chelant groups, by substituting for a hydrogen atom or hydroxyl group a bond or linkage to a macromolecule or polymer, e.g. a tissue specific biomolecule or a backbone polymer such as polylysine or polyethyleneimine which may carry several chelant groups and may itself be attached to a macromolecule to produce a bifunctional-polychelant. Such macromelecular derivatives of the compounds of formula I and the salts and metal chelates thereof form a further aspect of the present invention.
The linkage of a compound of formula I to a
macromolecule or backbone polymer may be effected by any of the conventional methods such as the carbodiimide method, the mixed anhydride procedure of Krejcarek et al. (see Biochemical and Biophysical Research
Communications 77: 581 (1977)), the cyclic anhydride method of Hnatowich et al. (see Science 220: 613 (1983) and elsewhere), the backbone conjugation techniques of Meares et al. (see Anal. Biochem. 142: 68 (1984) and elsewhere) and Schering (see EP-A-331616 for example) and by the use of linker molecules as described for example by Nycomed in WO-A-89/06979.
Formation of salts and chelates of the chelants of the invention may again be performed in a conventional manner.
The chelating agents of the present invention are particularly suitable for use in detoxification or in the formation of metal chelates, chelates which may be used for example in or as contrast agents for in vivo or in vitro magnetic resonance (MR), X-ray or ultrasound diagnostics (e.g. MR imaging and MR spectroscopy), or scintigraphy or in or as therapeutic agents for
radiotherapy, and such metal chelates form a
particularly important embodiment of the present
invention.
Salts or chelate complexes of the compounds of the invention containing heavy metal ions are particularly useful in diagnostic imaging or therapy. Especially preferred are salts or complexes with metals of atomic numbers 20-32, 42-44, 49 and 57 to 83, particularly Gd, Dy and Yb.
For use as an MR-diagnostics contrast agent, the chelated metal ion is particularly suitably a
paramagnetic ion, the metal conveniently being a
transition metal or a lanthanide, preferably having an atomic number of 21-29, 42, 44 or 57-71. Metal chelates in which the metal species is Eu, Gd, Dy, Ho, Cr, Mn or Fe are especially preferred and Gd , Mn and Dy are particularly preferred. For such use, the paramagnetic metal species is conveniently non-radioactive as
radioactivity is a characteristic which is neither required nor desirable for MR-diagnostics contrast agents. For use as X-ray or ultrasound contrast agents, the chelated metal species is preferably a heavy metal species, for example a non-radioactive metal with an atomic number greater than 37, preferably greater than 50, e.g. Dy 3+. For use in scmtigraphy and radiotherapy, the chelated metal species must of course be radioactive and any conventional complexable radioactive metal isotope, such as 99mTc or 111In for example, may be used. For radiography, the chelating agent may be in the form of a metal chelate with for example 67Cu, 153Sm or 90Y.
For use in detoxification of heavy metals, the chelating agent must be in salt form with a
physiologically acceptable counterion, e.g. sodium, calcium, ammonium, zinc or meglumine, e.g. as the sodium salt of the chelate of the compound of formula I with zinc or calcium.
Where the metal chelate carries an overall charge, such as is the case with the prior art Gd DTPA, it will conveniently be used in the form of a salt with a
physiologically acceptable counterion, for example an ammonium, substituted ammonium, alkali metal or alkaline earth metal cation or an anion deriving from an
inorganic or organic acid. In this regard, meglumine salts are particularly preferred.
Viewed from a further aspect, the present invention provides a diagnostic or therapeutic agent comprising a metal chelate, whereof the chelating entity is the residue of a compound of formula I or salt thereof, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation
therewith or for inclusion in a pharmaceutical
formulation for human or veterinary use.
Viewed from another aspect, the present invention provides a detoxification agent comprising a chelating agent according to the invention in the form of salt with a physiologically acceptable counterion, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation therewith or for inclusion in a pharmaceutical formulation for human or veterinary use.
The diagnostic and therapeutic agents of the present invention may be formulated with conventional pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. and may be in a form suitable for parenteral or enteral
administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the agent of the present invention may be in a conventional
pharmaceutical administration form such as a tablet, capsule, powder, solution, suspension, dispersion, syrup, suppository, etc; however, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.
The compounds according to the invention may therefore be formulated for administration using
physiologically acceptable carriers or excipients in a manner fully within the skill of the art. For example, the compounds, optionally with the addition of
pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized. Suitable additives include, for example, physiologically
biocompatible buffers (as for example, tromethamine hydrochloride), additions (e.g., 0.01 to 10 mole
percent) of chelants (such as, for example, DTPA, a DTPA-bisamide or non-complexed chelants of formula I) or calcium chelate complexes (as for example calcium DTPA, CaNaDTPA-bisamide, calcium salts or chelates of chelants of formula I), or, optionally, additions (e.g., 1 to 50 mole percent) of calcium of sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate combined with metal chelate complexes of chelants formula I and the like).
If the compounds are to be formulated in suspension form, e.g., in water or physiological saline for oral administration, a small amount of soluble chelate may be mixed with one or more of the inactive ingredients traditionally present in oral solutions and/or
surfactants and/or aromatics for flavouring.
For MRI and for X-ray imaging of some portions of the body the most preferred mode for administering metal chelates as contrast agents is parenteral, e.g.,
intravenous administration. Parenterally administrable forms, e.g., intravenous solutions, should be sterile and free from physiologically unacceptable agents, and should have low osmolality to minimize irritation of other adverse effects upon administration, and thus the contrast medium should preferably be isotonic or
slightly hypertonic. Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium
Chloride Injection, Lactated Ringer's Injection and other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack
Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th ed. Washington:
American Pharmaceutical Association (1975). The
solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will not interfere with the manufacture, storage or use of products.
Where the diagnostic or therapeutic agent comprises a chelate or salt of a toxic metal species, e.g. a heavy metal ion, it may be desirable to include within the formulation a slight excess of the chelating agent, e.g. as discussed by Schering in DE-A-3640708, or more preferably a slight excess of the calcium salt of such a chelating agent.
For MR-diagnostic examination, the diagnostic agent of the present invention, if in solution, suspension or dispersion form, will generally contain the metal chelate at concentration in the range 1 micromole to 1.5 mole per litre, preferably 0.1 to 700mM. The diagnostic agent may however be supplied in a more concentrated form for dilution prior to administration. The
diagnostic agent of the invention may conveniently be admi .ni.stered in amounts of from 10-3 to 3 mmol of the metal species per kilogram of body weight, e.g. about 1 mmol Gd/kg bodyweight.
For X-ray examination, the dose of the contrast agent should generally be higher and for scintigraphic examination the dose should generally be lower than for MR examination. For radiotherapy and detoxification, conventional dosages may be used.
Viewed from a further aspect, the present invention provides a method of generating enhanced images of the human or non-human animal body, especially the liver, which method comprises administering to said body a diagnostic agent according to the present invention and generating an X-ray, MR-diagnostics, ultrasound or scintigraphic image of at least a part thereof.
Viewed from a further aspect, the present invention provides a method of radiotherapy practised on the human or non-human animal body, which method comprises
administering to said body a chelate of a radioactive metal species with a chelating agent according to the invention.
Viewed from a further aspect, the present invention provides a method of heavy metal detoxification
practised on the human or non-human animal body, which method comprises administering to said body a chelating agent according to the invention in the form of a salt with a physiologically acceptable counterion.
Viewed from a yet further aspect, the present invention also provides the use of the compounds, especially the metal chelates, according to the
invention for the manufacture of diagnostic or
therapeutic agents for use in methods of image
generation, detoxification or radiotherapy practised on the human or non-human animal body.
Viewed from a still further aspect, the present invention provides a process for the preparation of the metal chelates of the invention which process comprises admixing in a solvent a compound of formula I or a salt (e.g. the sodium salt) or chelate thereof together with an at least sparingly soluble compound of said metal, for example a chloride, oxide or carbonate.
Viewed from a yet still further aspect, the present invention provides a process for the preparation of the diagnostic or therapeutic agent of the present
invention, which comprises admixing a metal chelate according to the invention, or a physiologically
acceptable salt thereof, together with at least one pharmaceutical or veterinary carrier or excipient.
Viewed from a yet still further aspect, the present invention provides a process for the preparation of the detoxification agent of the invention, which comprises admixing a chelating agent according to the invention in the form of a salt with a physiologically acceptable counterion together with at least one pharmaceutical or veterinary carrier or excipient.
The disclosures of all of the documents mentioned herein are incorporated by reference.
The present invention will now be illustrated further by the following non-limiting Examples. All ratios and percentages given herein are by weight and all temperatures are in degrees Celsius unless otherwise indicated.
Example 1
3,6,9,12-Tetraaza-6.9-bis(carboxymethyl)-4,11-dioxo- 2,13-diphenyltetradecane
EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 1-phenylethylamine 0.9 g (7.8 mmol) in dried acetonitrile (40 ml) at ambient
temperature and under a nitrogen atmosphere. The solution was heated to reflux temperature (85 °C) and refluxed for 20 hours. The mixture was then cooled, and the precipitate which had formed was isolated by
filtration and dried.
Yield 1.5g (77.1%).
The crude solid was dissolved in 20 ml water to which was added 1N NaOH to bring the pH to 10. After
adjusting the pH with HC1 (2N) to 3.5, the precipitate formed was filtered off and dried, and the title
compound was isolated.
Yield 1.06g (54.6%)
Melting point: 187-190°C. Example 2
3,6,9,12,15-Pentaaza-6.9.12-tris(carboxymethyl)-4,14- dioxo-l,17-diphenylheptadecane
DTPA-bis(anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 2-phenylethylamine 0.68 g (5.6 mmol) in dried chloroform (85 ml) at ambient
temperature. The stirred solution was left for 16 hours at ambient temperature. The precipitate which formed was isolated by filtration and dried. The crude product was then purified by reprecipitation as described in Example 1.
Yield: 0.89 g (53 %)
Melting point: 95-98°C.
Example 3
2,5,8,11,14-Pentaaza-5,8,11-tris(carboxymethyl)-3,13- dioxo-1,15-bis(pyrid-2-yl)pentadecane
DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 2-aminomethylpyridine 0.61 g (5.6 mmol) in dried chloroform at ambient temperature. The stirred solution was left for 42 hours at ambient temperature. The precipitate formed was isolated by filtration and dried.
Yield: 74.5%
Melting point: 107-110°C.
Example 4
1,4,7,10.13-Pentaaza-4,7,10-triscarboxymethyl-2,12-dioxo-1,13-bis(N-benzyl-piperidin-4-yl)tridecane
DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 4-amino-1-benzylpiperidine 1.07 g (5.6 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was then heated to reflux temperature. The solution was refluxed with stirring overnight under a nitrogen atmosphere. The solution was then evaporated until 25-30 ml remained. Subsequently ether (120ml) was added, and the precipitate was
filtered off and dried.
Yield: 93.2g
Example 5
1,4,7,10,13-Pentaaza-4,7,10-tris(carboxymethyl)-2,12-dioxo-1,13-bis(indan-2-yl)tridecane
DTPA-bis (anhydride) 0.88 g (2.48 mmol) was gradually added to a stirred solution of 2-aminoindane 0.66 g (4.955 mmol) in dried acetonitrile (40 ml) at ambient temperature. The solution was heated to reflux
temperature (85°C) and refluxed under a nitrogen
atmosphere for 4 hours. The reaction mixture was subsequently cooled, and the solution was decanted. The crude solid thereby obtained was dissolved in water with IN NaOH added to bring the pH to 13. After adjusting the pH with HCl (1N) to 3.5, the precipitate formed was filtered off and dried.
Yield: 47.2%
Example 6
1,4,7,10-Tetraaza-4,7-bis(carboxymethyl)-2,9-dioxo-1,10-bis(indan-2-yl)decane
EDTA-bis (anhydride) 0.38 g (1.46 mmol) was gradually added to a stirred solution of 2-aminoindane 0.39 g (2.93 mmol) in dried chloroform (30 ml) at ambient temperature. After 24 hours the precipitate formed was isolated by filteration and dried. The crude product was then purified by reprecipitation as described in
Example 1.
Yield: 0.43 g (56.4%)
Melting point: 199.5-202°C
Example 7
2,5,8,11-Tetraaza-5,8-bis(carboxymethyl)-3,10-dioxo- 1,12-diphenyldodecane
EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of benzylamine 0.83 g (3.9 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was heated to reflux temperature (70°C) and refluxed under a nitrogen atmosphere for 19 hours. The reaction mixture was subsequently cooled, and the precipitate formed was filtered off and dried.
Yield: 1.69 g (92.09%)
Melting point: 139-141°C
Example 8
1,4,7,10-Tetraaza-4,7-bis(carboxymethyl)-2,9-dioxo-1,10-bis(pyrid-2-yl) decane lg (3,9 mmol) EDTA-bis (anhydride) was gradually under stirring to acetonitrile (33 ml) heated to boiling. The mixture was refluxed for 1/2 h and 0.73g (1.1 mmol) 2-aminopyridine dissolved in 7 ml acetonitrile was
gradually added.
The reaction mixture was refluxed under nitrogen
atmosphere for 40 hours, subsequently cooled to ambient temperature and the precipitate formed was filtered off and dried .
Yield: 92 . 8%
Melting point : 215-217 C .
Example 9
1 ,4,7,10,13-Pentaaza-4,7,10-tris(carboxymethyl)-2,12- dioxo-1,13-bis(N-benzylpiperidin-4-yl)tridecane
DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 4-amino-1-benzylpiperidine 1.07 g (5.6 mmol) in dried chloroform (100 ml) at ambient temperature. The stirred solution was left at ambient temperature for 66 hours. Then about 50% of the chloroform was evaporated off. Ether (50 ml) was then added, and the precipitate formed was filtered off and dried.
Yield: 92.8%
Example 10
1,4,7,10-Tetraaza-4,7-bis(carboxymethyl)-2,9-dioxo-1,10-bis(N-benzylpiperidin-4-yl) decane
DTPA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 4-amino-l-benzylpiperidine 1.48 g (7.8 mmol) in dried chloroform (85 ml) at ambient temperature. The stirred solution was left for 18 hours at ambient temperature. The solution was evaporated until 25-30 ml remained. Subsequently ether (2 × 100 ml) was added. The precipitate formed was isolated by filtration and dried.
Yield: 91.9%
Melting point: 105-111°C. Example 11
3,6,9,12-Tetraaza-6,9-bis(carboxymethyl)-4,11-dioxo- 1,14-diphenyltetradecane
EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 2-phenylethylamine 0.9 g (7.8 mmol) in dried acetonitrile (40 ml) at ambient
temperature under a nitrogen atmosphere. The solution was heated to reflux temperature (85°C) and refluxed for 17 hours. The reaction mixture was subsequently cooled, and the precipitate formed was isolated by filtration and dried.
Yield: 1.7 g (87.8%)
Example 12
4 ,7,10,13,16-Pentaaza-7,10,13-tris(carboxymethyl)-5,15- dioxo-1,19-bis (morpholino) nonadecane
DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of N-(3-aminopropyl)morpholine 0.81 g (5.6 mmol) in dried chloroform (85 ml) at ambient temperature. The solution was stirred for 27 hours and then refluxed under a nitrogen atmosphere for 69 hours. The solution was evaporated until 25-30 ml remained.
Subsequently ether (120ml) was added. The precipitate formed was isolated by filtration and dried.
Yield: 93.9%
Example 13
2,5,8,11,14-Pentaaza-5,8,11-tris(carboxymethyl)-3,15-dioxo-1,15-bis(pyrid-3-yl)pentadecane
DTPA-bis (anhydride) 1.0 g (2.8 mmol) was gradually added to a stirred solution of 3-aminomethylpyridine 0.61 g (5.6 mmol) in dried acetonitrile (40 ml) at ambient temperature. The solution was stirred for 84 hours. The precipitate formed was isolated by filtration and dried.
Yield: 87.6%
Example 14
2,5,8,11-Tetraaza-5,8-bis(carboxymethyl)-3,10-dioxo- 1,12- bis(pyrid-3-yl)dodecane
EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 3-aminomethylpyridine 0.84 g
(7.8 mmol) in dried chloroform (85 ml) at ambient temperature. The precipitate formed was isolated by filtration and dried.
Yield: 97.8%
Melting point: 212-216°C
Example 15
2,5,8,11-Tetraaza-5,8-bis(carboxymethyl)-3,10-dioxo-1,12- bis(pyrid-2-yl)dodecane
EDTA-bis (anhydride) 1.0 g (3.9 mmol) was gradually added to a stirred solution of 2-aminomethylpyridine 0.84 g (7.8 mmol) in dried chloroform (120 ml) at ambient temperature. The stirred solution was left for 16 hours at ambient temperature. The solution was evaporated until 25-30 ml remained. Subsequently ether (50 ml) was added. The precipitate formed was isolated by
filteration and dried.
Yield: 98.4%
Melting point: 73-81ºC. Example 16
3,6,9,12-Tetraaza-2,13-bis(benzyloxycarbonyl)-6,9- bis(carboxymethyl)-4,11-dioxo-1,14-diphenyltetradecane
EDTA-bis (anhydride) (0.4 g, 1.56 mmol) was added in portions to a solution of H-Phe-OBzl-HCl (0.91 g, 3.12 mmol) and triethylamine (0.32 g, 3.12 mmol) in
chloroform (50 ml). The reaction mixture was stirred at ambient temperature for 20 hours before the white precipitated product was collected by filtration and dried under vacuum at 50°C.
Yield: 0.83 g (69%),
Melting point: 174-178°C
Elemental analysis:
calculated: C 65.78 H 6.05, N 7.30
found: C 65.53, H 6.15, N 7.14
1H NMR (DMSO): δ 8.32 (d, J 8.06 Hz, 2H), 7.5-7.08 (m,
20H), 5.10 (S, 4H), 4.70-4.50 (m, 2H), 3.50-2.41 (m,
16H).
Example 17
3,6,9,12,15-Pentaaza-2,16-bis(benzyloxycarbonyl)-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-diphenylheptadecane
DTPA-bis (anhydride) (0.56 g, 1.56 mmol) was added in portions to a solution of H-Phe-OBzl-HCl (0.91 g, 3.12 mmol) and triethylamine (0.32 g, 3.12 mmol) in
chloroform (50 ml). The reaction mixture was refluxed under N2 for 24 hours before the white precipitated product was collected by filtration and dried under vacuum at 50°C.
Yield: 1.1 g (81%),
Melting point: 120-126°C
1H NMR (DMSO): δ 8.45 (d, J 7.78 Hz, 2H), 7.50-7.05 (m, 20H), 5.10 (s, 4H), 4.70-4.50 (m, 2H), 3.70-2.60 (m, 22H) .
Example 18
3,6,9,12-Tetraaza-2,13-dicarboxy-6,9-bis(carboxymethyl)-4,11-dioxo-1,14-diphenyltetradecane
LiOH (0.34 g, 14.3 mmol) was added to a suspension of EDTA-bis (benzylphenylalanyl) amide (1.1 g, 1.43 mmol) in a mixture of methanol/water (3:1, 44 ml). After 2 hours the TLC showed that the hydrolysis was completed.
Methanol was removed under reduced pressure and the reaction mixture acidified to pH 3.5 with 2N HCl. The product was collected by filtration and dried under vacuum at 50ºC.
Yield: 0.89 g,
Melting point: 115-120°C
1H NMR (DMSO): δ 8.22 (d, J 7.4 Hz, 2H), 7.50-7.08 (m, 1 OH), 4.61-4.35 (m, 2H), 3.40-2.40 (m, 16H).
Example 19
3,6,9.12,15-Pentaaza-2,16-dicarboxy-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-diphenylheptadecane
LiOH (0.30 g, 12.7 mmol) was added to a suspension of DTPA-bis (benzylphenylalanyl) amide (1.1 g, 1.27 mmol) in a mixture of methanol/water (3:1, 44 ml). After 2 hours the TLC showed that the hydrolysis was completed. The solvent was removed under reduced pressure and the residue dried under vacuum at 50 °C to give 1.04 g of crude product.
1H NMR (DMSO): δ 8.49 (d, J 1.6 Hz, 2H), 7.40-7.00 (m, 1 OH), 4.43-4.20 (m, 2H) , 3.61-2.55 (m, 22H). Example 20
3,6,9,12-Tetraaza-6,9-bis(carboxymethyl)-4,11-dioxo- 1,14-bis(pyrid-2-yl)tetradecane
A solution of 2-(2-aminoethyl) pyridine (0.95 g, 7.8 mmol) and EDTA-bis (anhydride) (1.0 g, 3.9 mmol) in 85 ml chloroform was stirred for 4 days at ambient
temperature. Most of the chloroform was evaporated.
The rest (20-30 ml) was dissolved in 100 ml diethylether to crystallize. The solid product was collected and dried under reduced pressure to yield 88% product.
Melting point: 60-64°C
Elemental analysis:
Calculated: C 56.05 H 6.25
Found: C 55.88 H 6.25
1H NMR (200 MHz DMSO-d6) δ ppm: 2.66 (s, 4H, t, 4H, J =
7.1 Hz), 3.20 (s, 4H), 3.33 (s, 4H), 3.4-4.6 (m, 4H),
7.1-7.3 (m, 4H), 7.6-7.8 (m, 2H), 8.10 (t, 2H, 5.7 Hz),
8.50 (d, 2H, J = 4.7 Hz).
Example 21
3 ,6,9,12,15-Pentaaza-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-bis(pyrid-2-y1)heptadecane
2-(2-Aminoethyl)pyridine (0.68 g, 5.6 mmol) and DTPA-bis (anhydride) (1.0 g, 2.8 mmol) were dissolved in 85 ml chloroform. The mixture was stirred for 22 hours at ambient temperature. The solid product was separated from the solution by filtration before being dried in vacuum to give 56% product.
Melting point: 110-118°C
Elemental analysis:
Calculated: C 53.36 H 6.18
Found: C 57.58 H 6.46
1H NMR (200 MHz DMSO-d6) δ ppm: 2.8-3.8 (m, 30H), 7.1-7.4 (m, 4H) , 7 . 6-7 . 8 (m, 2H) , 8 . 1-8 . 3 (m, 2H) , 8 . 49 (d, 2H, 4 . 8 Hz ) .
Example 22
3,6,9,12-Tetraaza-2,13-dicarboxy-6.9-bis(carboxymethyl)- 4,11-dioxo-1,14-bis(indol-3-yl)tetradecane
Triethylamine (0.39 g, 3.9 mmol), tryptophanmethylester
(HCl) and EDTA-bis (anhydride) (0.5 g, 1.95 mmol) were dissolved in 70 ml chloroform. The suspension was stirred for 21 hours at ambient temperature. The solid product was collected by filtration and dried in vacuum to give 83% yield.
Melting point: 84-91°C
Elemental analysis:
Calculated: C 53.30 H 4.46
Found: C 58.94 H 5.83
1H NMR (200 MHz DMSO-d6) δ ppm: 2.26 (3, 4H), 3.0-3.4 (m,
14H), 3.60 (s, 6H) , 4.5-4.7 (m, 2H) , 6.95-7.15 (m, 4H),
7.19 (d, 2H, J = 1.8 Hz), 7.37 (d, 2H, J = 7.5 Hz) , 7.52
(d, 2H, 7.7 HZ), 8.27 (d, 2H, J = 7.7 Hz).
Example 23
3,6,9,12-Pentaaza-2,16-dicarboxy-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-bis(indol-3-yl)heptadecane
Triethylamine (0.57 g, 5.6 mmol), tryptophanmethylester (HCl) (1.43 g, 5.6 mmol) and DTPA-bis (anhydride) (1.000 g, 2.8 mmol) were dissolved in 100 ml chloroform. The mixture was refluxed in a nitrogen atmosphere for 3 days. Most of the chloroform was removed (20-30 ml left). 100 ml diethylether was added to the
concentrated solution. The crystalline product was collected by filtration, dissolved in basic aqueous solution and recrystallized with 0.5 M HCl.
The identity of the product as the title compound was verified by 1H and 13C NMR.
Example 24
3,6,9,12-Tetraaza-2,13-bis(methyloxycarbonyl)-6,9- bis(carboxymethyl)-4,11-dioxo-1,14-bis(indol-3- yl)tetradecane
Lithium hydroxide (14.4 mg, 0.61 mmol) was dissolved in a 4.5 ml mixture of MeOH/H2O(3:1). 3,6,9,12-Tetraaza- 2,13,-bis(methyloxycarbonyl)-6,9-bis(carboxymethyl)- 4,11-dioxo-1,14-bis(indol-3-yl)tetradecane (60.0 mg, 8.7 × 10-2 mmol) was added and the solution was stirred for 8 hours. Methanol was removed, 2 ml water was added and the pH was adjusted to 3.5 (0.5 M HCl). The solid product was collected and dried in vacuo for 12 hours. The identity of the product as the title compound was verified by 1Η. NMR.
Example 25
3,6,9,12,15-Pentaaza-2,16-bis(methyloxycarbonyl)-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-bis(indol-3-yl)heptadecane
Lithium hydroxide (0.32 g, 13.4 mmol) was dissolved in a mixture of MeOH/H2O (3:1). 3,6,9,12,15-Pentaaza-2,16,-bis(methyloxycarbonyl)-6,9,12-tris(carboxymethyl)-4,14-dioxo-1,17-bis(indol-3-yl)heptadecane (1.33 g, 1.67 mmol) was added and the solution was stirred for 6 hours at ambient temperature. Methanol was evaporated and 10 ml water was added to the residual. The pH was adjusted to 3.5 with 0.5 M HCl. The solid product was collected by filtration and dried to give 18% product.
Melting point: 158-160°C
Elemental analysis:
Calculated: C 55.86 H 5.80
Found: C 56.45 H 5.67
1H NMR (200 MHz, DMSO-d6) δ ppm: 2.5-3.6 (m, 22H), 4.40 4.7 (m, 2H), 6.9-7.2 (m, 4H), 7.22 (s, 2H), 7.36 (d, 2H,
J = 7.5 Hz), 7.56 (d, 2H, J= 7.4 Hz), 8.27 (d, 2H, J =
8.1 Hz).
Example 26
General procedure for complexation with Gadolinium (20 mM solution)
GdCl3 (1 mmol) in 4 ml water was dropwise added to a solution of a chelant of formula I (where n is 1) (1 mmol) in 30 ml water, while the pH was kept at 5-6 by adding 1 N NaOH. After addition the mixture was stirred for 1/2 hour and diluted with water to 50 ml.
Example 27
General procedure for complexation with Manganese (50 mM solution)
MnCl2 (1.25 mmol) in 3 ml water was dropwise added to a solution of a chelant of formula I (where n is 0) (1.25 mmol) in 15 ml water, while the pH was kept at 5-6 by adding 1N NaOH. After addition the mixture was stirred for 1/2 hour and diluted with water to 25 ml. Example 28
Relaxivity of Gd and Mn chelates in water and AutonormR measured at 37ºC, 20 MHz on an IBM PC/20 Series NMR Analyzer (Minispec).

Claims

Claims
1. A compound of formula I
(wherein n is 0 or 1;
one group R1 is a group NR11R14 where R11 is a hydroxyl or alkoxy group or a group -L-Cy or -O-L-Cy, and R14 is a hydrogen atom, an alkyl group or a group -L-Cy, and the other group R1 is a hydroxyl group or a group NR11R14; L is a bond or a straight-chain or branched saturated or unsaturated alkylene group optionally interrupted by a carbocyclic or heterocyclic saturated or unsaturated group and optionally attached to the Cy group by a peptide or carbonyl link and optionally substituted by further Cy groups or by aminocarbonyl, acyl or acylamino groups; and Cy is a cyclic lipophilic group; with the provisos that in any NR11R14 group one of R11 and R14 comprises a L-Cy group and that where n is 1 at least one R1 group is other than phenylamine, benzylamine, or methoxybenzylamine) and metal chelates and salts
thereof.
2. A compound as claimed in claim 1 containing at least one Cy group which is a carbocyclic or
heterocyclic saturated or unsaturated group itself optionally carrying one or more fused carbocyclic or heterocyclic saturated or unsaturated rings and
optionally substituted by halogen atoms, alkyl,
alkylamino, dialkylamino, carbamoyl, N-alkylcarbamoyl, acetamido, N-alkylacetamido or carbocyclic or
heterocyclic saturated or unsaturated groups.
3. A compound as claimed in either of claims 1 and 2 containing at least one Cy group selected from
optionally substituted benzene, pyridine, pyrimidine, pyrazine, 1,3-oxazine, 1,4-oxazine, 1,3-thiazine, 1,4- thiazine, pyrrole, imidazole, 1,3-oxazole, 1, 3-thiazole, furan, thiophene, piperidine, piperazine, morpholine, perhydro-l,4-thiazine and pyrrolidine rings.
4. A compound as claimed in any one of claims 1 to 3 containing at least one Cy group selected from groups of formula la to Ie
(where R3 to R8 is each independently a bond or a
hydrogen or halogen atom or an alkyl, alkylamino,
dialkylamino, carbamoyl, N-alkylcarbamoyl, acetamido or N-alkylacetamido group or two adjacent groups from R3 to R8 together form a C2-5 alkylene or azaalkylene bridge, the point of attachment to L being a carbon of said bridge or one of said groups R3 to R8; X is nitrogen or CH and Y is CH or nitrogen; X' is CH2, NH, oxygen, sulphur or a bond; X" is nitrogen, oxygen or sulphur and Y" is CH or nitrogen; and R9 is a bond or hydrogen, alkyl or aralkyl).
5. A compound as claimed in any one of claims 1 to 4 containing at least one group LCy of formula
- (CHR10) k- (CO) a- (NR10) b- (CO) C-R10 where k is 0-10; a, b and c are 0 or 1, the sum of a and c being 0 or 1; each R10 is a hydrogen atom, an alkyl group, an optionally esterified carboxyl group or a group Cy, at least one being a group Cy, and one or more CHR10 moieties may optionally be replaced by a 5-7 membered saturated homo or heterocyclic ring.
6. A compound as claimed in any one of claims 1 to 5 wherein at least one group R1 is a group NR11R14 wherein R11 is a group -L-Cy and R14 is a hydrogen atom or an alkyl group.
7. A compound as claimed in any one of claims 1 to 6 being a compound of formula II
(where n is 0 or 1, R15 is hydrogen or methyl
and R13 is a group selected from benzyl, 2-phenyl-ethyl, 1-phenyl-ethyl, pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 3-morpholino-propyl, N-benzyl-piperidin-4-yl and indanyl groups and iodinated such groups) or a metal chelate or salt thereof.
8. A compound as claimed in any one of claims 1 to 7 being a metal chelate of a compound of formula I, said metal being a paramagnetic ion of an element of atomic number 21-29, 42, 44 or 57-71.
9. A compound as claimed in claim 8 being a chelate of Gd, Mn or Dy.
10. A therapeutic or diagnostic composition comprising a compound of formula I or metal chelate thereof as defined in any one of claims 1 to 9 or a physiologically tolerable salt thereof together with at least one pharmaceutical or veterinary carrier or excipient.
11. A process for the preparation of compound, as claimed in claim 1 said process comprising reacting EDTA or DTPA or an activated or protected derivative thereof with an amine of formula III
HNR11'R14' (III) where R11' and R14' are groups R11 and R14 as defined in claim 1 or protected such groups, followed where desired by deprotection, metallation or salt formation.
12. A method of generating enhanced images of the human or non-human animal body, which method comprises
administering to said body a metal chelate of a compound of formula I as defined in claim 1 or a physiologically tolerable salt thereof and generating an X-ray,
MR-diagnostics, ultrasound or scintigraphic image of at least a part thereof.
13. A method of radiotherapy practised on the human or non-human animal body, which method comprises
administering to said body a chelate of a radioactive metal species with a chelating agent of formula I as defined in claim 1 or a physiologically tolerable salt thereof.
14. A method of heavy metal detoxification practised on the human or non-human animal body, which method
comprises administering to said body a chelating agent which is a salt of a compound of formula I as defined in claim 1 with a physiologically acceptable counterion.
15. The use of compounds as claimed in claim 1 for the manufacture of diagnostic or therapeutic agents for use in methods of image generation, detoxification or radiotherapy practised on the human or non-human animal body.
EP92901385A 1990-12-21 1991-12-20 Chelating agents Withdrawn EP0563145A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9027922 1990-12-21
GB909027922A GB9027922D0 (en) 1990-12-21 1990-12-21 Compounds

Publications (1)

Publication Number Publication Date
EP0563145A1 true EP0563145A1 (en) 1993-10-06

Family

ID=10687517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901385A Withdrawn EP0563145A1 (en) 1990-12-21 1991-12-20 Chelating agents

Country Status (5)

Country Link
EP (1) EP0563145A1 (en)
JP (1) JPH06504273A (en)
CA (1) CA2098712A1 (en)
GB (1) GB9027922D0 (en)
WO (1) WO1992011232A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562894A (en) * 1991-08-09 1996-10-08 Regents Of The University Of California Amino-acyl-type and catecholamine-type contrast agents for MRI
EP0598837A4 (en) * 1991-08-09 1994-07-13 Univ California Amino acid, ester and/or catechol contrast agents for mri.
CA2116867C (en) † 1992-07-03 2004-04-27 The Green Cross Corporation Novel chelating agent, complex compound of said chelating agent and metallic atom, and diagnostic agent comprising same
AU671465B2 (en) * 1992-07-31 1996-08-29 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US5807535A (en) * 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
EP0955066A3 (en) * 1992-07-31 2002-08-28 Australian Nuclear Science And Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
DE19507820A1 (en) * 1995-02-21 1996-08-22 Schering Ag Novel substituted DTPA derivatives, their metal complexes, pharmaceutical compositions containing these complexes, their use in diagnostics, and methods for producing the complexes and compositions
EP1343758A1 (en) * 2000-11-08 2003-09-17 K.U. Leuven Research & Development Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
DE102020214114A1 (en) 2020-11-10 2022-05-12 Henkel Ag & Co. Kgaa Metal complexes and dishwashing detergents containing them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786946A (en) * 1971-07-29 1973-01-29 Ciba Geigy CHELATES TO COMBAT SYMPTOMS OF METAL DEFICIENCY IN BIOLOGICAL SYSTEMS
CH569405A5 (en) * 1972-07-11 1975-11-28 Ciba Geigy Ag Combatting metal deficiency in biological systems - with metal chelates of ethylene diamine tetraacetic acid diamide derivs
DE2511891A1 (en) * 1975-03-19 1976-10-07 Gruenenthal Chemie Anti-thrombotic dioxo-piperazine derivs - prepd. e.g. by cyclising N,N,N',N'-1,2-alkylene-diamine-tetraacetic acids with amines
DE3324235A1 (en) * 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen NEW COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
DE3927444A1 (en) * 1989-08-16 1991-02-28 Schering Ag USE OF AMID COMPLEX COMPOUNDS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9211232A1 *

Also Published As

Publication number Publication date
GB9027922D0 (en) 1991-02-13
JPH06504273A (en) 1994-05-19
WO1992011232A1 (en) 1992-07-09
CA2098712A1 (en) 1992-06-22

Similar Documents

Publication Publication Date Title
US5322681A (en) Chelating compounds
CA1253799A (en) Nmr contrast agents
US5348954A (en) Heterocyclic chelating agents
IE910189A1 (en) Chelants
EP0594734B1 (en) Hydroxamate and hydrazide derivatives of polyamines and their medical use as chelating agents
US5556968A (en) Polyazamacrocycle chelating agents with amide linkages
EP0717737A1 (en) Chelants as contrast enhancing agents
EP0563145A1 (en) Chelating agents
HUT76805A (en) Macrocyclic chelants, their chelates and uses thereof in the diagnostic field
WO1991015467A1 (en) Aminopolycarboxylic acid chelating agents
WO1991015466A2 (en) Aminopolycarboxylic acid chelating agents
CA2177271A1 (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceuticals containing them and process for their production
AU646795C (en) Heterocyclic chelating agents
WO1990008134A1 (en) Chelating agent derivatives
IE911182A1 (en) Chelating agents
AU644627B2 (en) Chelating compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19931116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940527